Document is current
Any future updates will be listed below
-
Authors
Fabbri, C
Tansey, K E
Perlis, R H
Hauser, J
Henigsberg, N https://orcid.org/0000-0002-5303-1834
Maier, W
Mors, O
Placentino, A
Rietschel, M
Souery, D
Breen, G https://orcid.org/0000-0003-2053-1792
Curtis, C
Sang-Hyuk, L
Newhouse, S
Patel, H
Guipponi, M
Perroud, N
Bondolfi, G
O'Donovan, M
Lewis, G
Biernacka, J M
Weinshilboum, R M
Farmer, A
Aitchison, K J
Craig, I
McGuffin, P
Uher, R
Lewis, C M
- License Information
-
More Information
Article History
Received: 17 February 2017
Revised: 2 June 2017
Accepted: 7 June 2017
First Online: 21 November 2017
Competing interests
: NH participated in clinical trials sponsored by pharmaceutical companies including GlaxoSmithKline and Lundbeck. DS is serving in national advisory boards or consulting for Janssen, TEVA, GlaxoSmithKline. His center is receiving unrestricted financial support from Lundbeck and Fondation René de Spoellberghe. WM, KJA, AEF and PMcG have received consultancy fees and honoraria for participating in expert panels from pharmaceutical companies including Lundbeck and GlaxoSmithKline and Roche Diagnostics. RHP reported serving on scientific advisory boards or consulting for Genomind LLC, Healthrageous, Pfizer, Perfect Health, Proteus Biomedical, PsyBrain and RID Ventures LLC and reported receiving royalties through Massachusetts General Hospital from Concordant Rater Systems (now Bracket/Medco). NP received honoraria for participating in expert panels from pharmaceutical companies including Lundbeck. GB is a member of a national advisory board for Bristol-Myer Squibb and Pfizer and has received research funding from GlaxoSmithKline, Wyeth-Lederle, Bristol-Myers-Squibb and Sanofi Aventis. The department of MO’D received £2000 in lieu of an honorarium to MO’D from Lilly as a result of his participation in sponsored symposia in 2012. Those symposia were unrelated to the contents of this manuscript. The other authors declare no conflict of interest.
